RxSpan MD Reviews: $249 Is the Month, $150 Is a Year

The one-sentence version

RxSpan MD publishes an all-inclusive price for NAD+ — consult, medication, supplies, shipping and support in one figure — and the month-to-month rate is $249, with $199, $166 and $150 available only on three-, six- and twelve-month plans. It is a physician-founded practice that names its founder, which almost nobody here does, and it says nothing whatsoever about the pharmacy that fills your prescription, which almost everybody else does. It grades A, 12 out of 14; the two missing points are the pharmacy factor, and the grade is computed from published terms alone and cannot see who pays us.

What it is, and who it's for

RxSpan MD is a telehealth practice founded by Dr John Diaz, a board-certified plastic surgeon with more than twenty years in practice — Cornell, Albert Einstein College of Medicine, Alpha Omega Alpha, five years as president of the Society of Plastic Surgeons. His page frames the origin honestly: patients came for appearance and asked about weight and wellness, and the practice grew into "helping patients extend their healthspan through thoughtfully prescribed medications." Naming a clinician at all puts RxSpan ahead of most of this field — see what a longevity doctor actually is.

Its longevity catalogue is wide: NAD+ by injection, nasal spray and flex-dose tablet, sermorelin ODT, glutathione, GHK-Cu, methylene blue, MIC B12, Lipo C and PT-141, beside a weight-loss line running from compounded semaglutide up to brand Wegovy at $1,349.

What it actually costs

All figures verified on rxspanmd.com on 26 July 2026, on the Longevity catalogue.

The catalogue. NAD+ Injection $249, NAD+ Nasal Spray $249, NAD+ Flex Dose Tablet $199, Sermorelin ODT $179, Glutathione $149, GHK-Cu $149, Lipo C $179, PT-141 $199, MIC B12 $129, Methylene Blue $99. Every single one of those numbers carries the same parenthetical beneath it: "(For the first month)."

The plan ladder behind it. Choosing a product opens a plan selector: Monthly $249/mo · 3-month plan $199/mo · 6-month plan $166/mo · 12-month plan $150/mo, with the three longer terms flagged "Max Saving." The overview beside it reads "Pre-paid monthly or quarterly," "Price includes consult, medication, supplies, shipping, and support," and "Cancel or change plans anytime."

So the honest summary is two sentences. $249 is a real, published, all-inclusive month-to-month price for NAD+ injection — better disclosed than most of this board, and the top of its range. Everything cheaper is a prepay, and the "(For the first month)" label means the catalogue number is not by itself a monthly commitment either.

You pay before you are assessed. The checkout footer states: "After checkout, a provider will review your information to determine if treatment is right for you. Prescription is not guaranteed." The default plan selection totals $597 — three months at $199. That is the number a buyer who clicks through without changing anything is charged, not $249 and certainly not $150.

And there is no refund policy. RxSpan publishes four legal documents — Terms of Service, Privacy Policy, Notice of Privacy Practices and Medical Consent — and none is a refund or cancellation policy. What happens to your $597 if the provider declines you is not stated anywhere public. Ask before you check out; see also what longevity care costs.

What's included, what's extra

Included, per the site: the consult, the medication, supplies, expedited shipping, and "unlimited appointments, messaging and support" with "24/7 access to a dedicated team of specialists." Sitewide badges promise "No Hidden Fees" and "Doctor-led Plans & Coaching."

Not offered: bloodwork, biomarker panels or any before-and-after testing. Nothing here measures whether the protocol did anything — the same structural gap most of this category has, and the reason longevity biomarker panels sit outside it.

Clinical oversight and the pharmacy

Oversight is genuinely above average on the disclosure axis: a named, credentialled founding physician, unlimited clinician access inside the price, and an explicit statement that a prescription is not guaranteed.

The pharmacy is the hole, and it is total. We read the site root, the About page, the product catalogue and the Terms of Service. The only sentence about dispensing anywhere is in the Terms: "If prescribed, medications may be fulfilled by licensed pharmacies." No facility, no address, no Section 503A claim, no 503B claim — not even the "compounded in the USA" badge most competitors manage. That is why RxSpan drops both pharmacy points on our rubric, and it is the single thing standing between this row and a perfect score.

Why that is not a formality: 503A compounders are state-licensed and specifically not subject to current good manufacturing practice requirements, while 503B outsourcing facilities register with FDA and must comply with them. Compounded drugs of either class are not FDA-approved¹ — and a buyer cannot look up a facility RxSpan will not name.

The evidence behind what it sells

RxSpan's own copy is restrained — it sells "healthspan" rather than reversal — but the molecules are the same ones the rest of this board oversells, and the trial record is what it is.

On NAD+: the 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific" with clinical effectiveness "inconclusive," and reported that no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for anti-aging or wellness indications². That bears directly on the $249 injection tier, and on any bioavailability argument for it over the $199 tablet. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time³.

On sermorelin: the trial of that exact molecule — GHRH 1-29, given nightly for six weeks to eleven healthy men aged 64–76 with low baseline IGF-1 — raised nocturnal growth hormone significantly while producing no change in IGF-1 and no change in DEXA-measured muscle or fat⁴. The landmark systematic review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events⁵. See NAD+ for longevity, peptides for longevity and what's proven versus hyped.

Where it's weak, and who should skip it

Skip it if you need to know who compounds your medication — RxSpan will not tell you, and no other row on our board is this silent. Skip it if paying before assessment with no published refund policy is a risk you will not take. And skip it if $249 is simply too much: it is the top of this board's month-to-month range for NAD+, and two A-graded competitors sit well below it.

If you proceed, choose the Monthly plan deliberately rather than accepting the $597 default, and ask two questions in writing first: which pharmacy fills the prescription, and what happens to your money if the provider declines you.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). RxSpan MD takes price transparency in full — one all-inclusive figure per product with the plan ladder shown, which is more than most of this board manages — plus four for a real longevity line, two for a consult inside the price, and two for unlimited clinician access. It takes zero on pharmacy, because it publishes no statement of any kind. Twelve of fourteen. An A.

The letter is right and the shape of it is unusual: this is the most clinician-forward row we grade and the least pharmacy-forward, at once. Publish a compounding standard and name a facility and it would be a fourteen tomorrow, without changing a single price. The full graded field is at our provider rankings; its neighbours are our Direct Meds review and Enhance MD review.